Health ❯ Healthcare

Chronic Conditions

Diabetes Obesity Heart Disease Hypertension Type 2 Diabetes Cardiovascular Health Diabetes Management Asthma Cardiovascular Disease Obesity Management

Semaglutide Cuts Heavy Drinking in 26-Week Trial

The trial points to GLP-1 effects on craving beyond weight.

Boehringer’s Dual-Agonist Survodutide Cuts Body Weight by Up to 16.6% in Phase III Trial

New Data Tie GLP-1 Drugs’ Broad Benefits to Inflammation

Tirzepatide Linked to Lower Death and Heart Events After PCI and TAVR in New Real-World Analyses

FDA Clears Dupixent as First Biologic for Young Children With Chronic Spontaneous Urticaria

Amazon Rolls Out Nationwide GLP-1 Care Program Through One Medical

CMS Pauses Medicare GLP-1 Pilot After Insurers Balk, Sets 2026–27 Bridge

Study Links Longer, Frequent, Morning Naps to Higher Death Risk in Older Adults

FDA Orders Post-Approval Safety Studies for Lilly’s Foundayo Weight-Loss Pill

Amazon Pharmacy Launches Same-Day Delivery for Lilly’s Foundayo Weight-Loss Pill

Insmed Halts Brensocatib in Hidradenitis Suppurativa After Phase 2b Trial Fails

ARPA-H Advances Three Knee Osteoarthritis Regeneration Projects Toward Human Trials

FDA Clears Lilly’s Foundayo Pill, Escalating GLP-1 Weight-Loss Rivalry

Trial Finds Stopping Beta-Blockers After Heart Attack Safe for Selected Low-Risk Patients

Screening Test Finds Hidden Heart Failure in One in Four High-Risk Diabetics

GLP-1 Drugs Linked to Lower Addiction Risk and Harm in Large VA Study

Evolocumab Cuts First Cardiovascular Events by 31% in High‑Risk Diabetes Without Known Atherosclerosis

FDA Approves Awiqli, First Once-Weekly Basal Insulin for Type 2 Diabetes

Senators Unveil Bipartisan INSULIN Act With $35 Cap and Uninsured Pilot

Eamonn Holmes Denies He Dozed Off On GB News, Says He Was Fixing a Mic